by jtcir-auto | Feb 2, 2021 | Press Releases
– Company secures next step to continue to build-out pipeline of assets- University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing pre-clinical studies for the prevention of coronavirus diseases,...
by jtcir-auto | Feb 2, 2021 | Press Releases
– Company secures next step to continue to build-out pipeline of assets- University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing pre-clinical studies for the prevention of coronavirus diseases,...
by jtcir-auto | Jan 28, 2021 | Press Releases
– Company licenses exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific immunosuppressive therapeutic proteins for the potential treatment of neuromyelitis optica spectrum disorder (“NMOSD”) from...
by jtcir-auto | Jan 28, 2021 | Press Releases
– Company licenses exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific immunosuppressive therapeutic proteins for the potential treatment of neuromyelitis optica spectrum disorder (“NMOSD”) from...
by jtcir-auto | Jan 26, 2021 | Press Releases
CHARLESTON, S.C., Jan. 26, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has...